Drug Trial Radar · NCT00104273
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
Last checked: Nov 20, 2026Latest source record: Jul 15, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
376
Actual
Start
Aug 2004
Primary completion
Mar 2007
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- Collaborators
- Eisai Inc.
- First posted
- Feb 25, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 45 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
Conditions
- Dementia
- Alzheimer's Disease
Interventions
RasagilineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cognitive Function
Locations
58 sites in 4 countries. Site status is shown where the registry gives one.
Collaborative Neuroscience Network
Huntsville, Alabama
North Alabama Neuroscience Research
Huntsville, Alabama
Northwest Neurospecialists, PLLC
Tucson, Arizona
Clinical Study Centers, LLC
Little Rock, Arkansas
East Bay Region Associates in Neurology
Berkeley, California
Margolin Brain Institute
Fresno, California
Collaborative Neuroscience Network
Garden Grove, California
San Francisco Clinical Research Center
San Francisco, California
Neurological Research Institute
Santa Monica, California
University of Colorado Health Sciences Center
Denver, Colorado
Premiere Research Institute
West Palm Beach, Florida
North Broward Medical Center/Memory Disorder Center
West Palm Beach, Florida
Emory University Wesley Woods Health Center
Altanta, Georgia
Dekalb Neurology Associates, LLC
Decatur, Georgia
Radiant Research
Chicago, Illinois
Fort Wayne Neurological Center
Fort Wayne, Indiana
Mid America Neuroscience Institute
Lenexa, Kansas
Four Rivers Clinical Research
Paducah, Kentucky
Tulane University Health Sciences Center, Dept of Psychiatry and Neurology
New Orleans, Louisiana
Department of Neurology - Brigham and Women's Hospital
Boston, Massachusetts
Northern Michigan Neurology
Traverse City, Michigan
University Behavioral Healthcare Centre Department of Psychiatry
Piscataway, New Jersey
Odyssey Research
Fargo, North Dakota
Ohio State University, Department of Neurology
Columbus, Ohio
Pahl Brain Associates
Oklahoma City, Oklahoma
Medical University of South Carolina Alzheimer's Research and Clinical Programs
North Charleston, South Carolina
Department of Neurology Baylor College of Medicine
Houston, Texas
Premiere Research Institute
Houston, Texas
University of Texas Mental Sciences Institute
Houston, Texas
Peninsula Internal Medicine Associates
Gig Harbor, Washington
Internal Medicine Northwest
Tacoma, Washington
Ballarat Health Service - Queen Elizabeth Center
Ballarat, Australia
Aged Mental Health Research Unit - Kingston Centre
Cheltenham, Australia
Prince Charles Hospital - Dept. of Geriatrics
Chermside, Australia
Central Coast Neuroscience Research
East Gosford, Australia
Heidelberg Repatriation Hospital
Heidelberg West, Australia
Hornsby Kur-ing-gai Hospital, Rehabilitation and Aged Care Service
Hornsby, Australia
St. George's Hospital
Kew, Australia
McCusker Foundation for Alzheimer's Disease Research
Nedlands, Australia
The Queen Elizabeth Hospital
Woodville, Australia
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.